By analyzing glucose and insulin tolerance test results in an animal model of nonalcoholic steatohepatitis, Yang et al. demonstrated that silencing Tgfbr2 may contribute to MetS manifestations, including weight gain and insulin resistance; their finding indicated that Tgfbr2 is a potent mediator in the development of hepatic steatosis, hepatocyte death, inflammation, and fibrosis12. Here, TGFBR2 is linked to fatty liver disease.